CXCL12 and colorectal carcinoma: The study by Stanisavljević showed an increased risk of recurrence with low/negative expression of cytoplasm CXCL12 in two cohorts of stage I–III CRC, with significant results in the multivariate analysis with a hazard ratio (HR) of 1.61 [(0.95–2.73), p = 0.075] in one cohort and an HR of 5.13 [(2.23–11.81), p < 0.001] in the other group (29) (Supplementary Tables 4-16).